<DOC>
	<DOCNO>NCT01141478</DOCNO>
	<brief_summary>This study design determine whether proton beam radiotherapy plus Sorafenib compare Sorafenib alone produce best result treat patient Hepatocellular Carcinoma .</brief_summary>
	<brief_title>Proton Beam Radiotherapy Plus Sorafenib Versus Sorafenib Patients With Hepatocellular Carcinoma Exceeding San Francisco Criteria</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Patients candidate receive proton beam sorafenib 2 . Patients tumor burden exceeds San Francisco criteria 1 . Patients candidate surgical resection 2 . Patients tumor burden within Milan and/or San Francisco criteria 3 . Patients contraindication receive proton 4 . Patients contraindication receive sorafenib include uncontrolled hypertension , coumadin treatment prior intolerability drug 5 . Patients treat previously locoregional treatment 6 . Patients prior liver transplant 7 . Patients child class C 8 . Patients model endstage liver disease ( MELD ) score &gt; 25 9 . Patients comorbid disease may impact survival 10 . Patients ongoing alcohol intake 11 . Patients active sepsis 12 . Patients gastrointestinal bleeding within week 13 . Patients unwilling sign inform consent form 14 . Patients history noncompliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Carcinoma , Hepatocellular</keyword>
	<keyword>Proton Beam Radiotherapy</keyword>
	<keyword>Sorafenib</keyword>
</DOC>